

Synthesis and Biological Evaluation of Podophyllotoxin Analogues as Potential Chemotherapeutic Agents

Madison Flint and Dr. Stéphane Roche

Florida Atlantic University - Department of Chemistry and Biochemistry

Can we synthesize Aza-Podophyllotoxin derivatives with high potency and selectivity for the treatment of colon cancer?

Introduction

Podophyllotoxin is a natural aryltetralin lignan compound isolated from the rhizomes or leaves of plants within the genus *Podophyllum* (*P. emodi* and *P. peltatum* respectively). Podophyllotoxin has been under extensive biochemical investigations since the discovery of its biological activity as a strong microtubule destabilizing agent during mitosis¹. Podophyllotoxin derivatives such as *etoposide*, *teniposide* and *etopophos* have since been produced and utilized as chemotherapeutic agents acting on topoisomerase II inhibition. Although these antineoplastic compounds have shown significant activity as cancerous cell growth inhibitors (large and small lung, testicular, stomach and pancreatic cancers)², they lack selectivity and are thus extremely toxic to healthy cells. This has led to a recent interest in the synthesis of Podophyllotoxin analogues in hopes of optimizing the biological selectivity and potency of the semi-synthetic derivatives already on the market. Our research efforts are directed towards synthesizing a derivative that effectively targets and treats specific colorectal cancers. Recent studies have shown that the progression of many colorectal cancers is linked to the secondary up-regulation event of the KRas and WNT oncogenic genes of tumor cells^{3,4}. Our goal is to synthesize aza-analogues that selectively inhibit this KRas-WNT synergistic activation in colorectal tumor cells via subsequent biological investigations with an assay known as the KRas synthetic lethal phenotypic module provided by the Eli Lilly pharmaceutical company.

Methods

The initial approach utilized for the generation of Aza-analogues was an optimized one-pot synthesis (Figure 1 of Image 1) obtained from previous literature. Investigations were pursued to determine a plausible mechanism in the cascade reaction involving tetrionic acid and aldehydes and anilines to generate the Aza-podophyllotoxin core structure. In general, it was found that this reaction proceeded through a crucial iminium ion intermediate that when considered, lead to a threefold increase in recorded yields⁵; the proposed mechanism can be observed in Figure 2 of Image 1. This mechanism first involves activation of the aldehyde component via condensation (facilitated by LUMO lowering effect of iminium ion) with an electron deficient "sacrificial aniline" to form an electrophilic iminium ion⁵. Upon condensation of the enolized tetrionic acid and the resulting iminium ion, the reaction was hypothesized to proceed through formation of a quinone-like species resulting in regeneration of the sacrificial aniline⁵. The aniline thus serves dual purpose in this synthetic cascade as it was proposed (supported with stereochemical evidence) to further react with the quinone-like species, eventually forming the desired Podophyllotoxin analogue⁵. Subsequent biological evaluation of the prepared library (Image 2) through the KRas synthetic lethal phenotypic module revealed that five analogues possessed promising activity in comparison to the parent Aza compound. Image 3 displays the results of the KRas-WNT inhibition assay for compound AH-I-80 and the parent derivative MH-I-002 (for comparison).







Image 3

KRAS Synthetic Lethal Phenotypic Module Results:

Parent compound MH-I-002 assay results:



Compound AH-I-80 assay results:




Image 4

Lilly
Answers That Matter.
OPEN INNOVATION
DRUG DISCOVERY



Results

Compounds AH-I-80, AH-I-90, AH-I-89 (MF-1-004, MF-1-012), MF-1-005 (NJ-4-016), and MF-1-014 (NJ-4-024) showed exceptional inhibitory activity of the synergistic KRas-WNT pathway. It can be seen from Image 3 that analogue AH-I-80 displays almost synonymous activity to the parent compound (MH-I-002) at significantly lower concentrations. The observed half maximal inhibitory concentration (IC₅₀) of AH-I-80 ranges from 0.002 μM – 0.004 μM while the parent compound displays an IC₅₀ range from 22 nM to 36 nM. The other active compounds displayed relatively important inhibitory activity but at slightly higher or similar concentrations than that of the parent compound.

Discussion

The KRAS synthetic lethal phenotypic module conclusions exhibit favorable results for compound AH-I-80. Podophyllotoxin and its analogues are potent anticancer agents that lack selectivity and thus, are toxic to healthy host cells. The IC₅₀ range of this compound (2 nM – 4 nM) reveals that AH-I-80 is about 10 times more potent than the parent compound with slightly lower inhibitory activity. Thus, a lower dose of compound AH-I-80 would yield similar activity to MH-I-002 towards inhibition of the KRas-WNT expression pathways in colorectal tumor cells. As a result of this, less healthy host cells would be effected by this activity and the overall toxicity of the compound would be notably less than that of the parent compound. These results are extremely remarkable and provide insight into possible chemotherapeutic applications of this compound. Although these results did not display the intended increase in selectivity towards cancerous cells, this increase in potency is extremely valuable for the design of a second generation compound-library. In conclusion, over 30 novel Aza-podophyllotoxin derivatives have been synthesized and several lead compounds have been determined to possess significant anticancer activity with increased potency in comparison to the parent (reference) compound which in the past has displayed superior activity. Not only has this research provided positive results for future applications but it has also provided me during my undergraduate experience with a vast amount of knowledge and exposure to modern chemical and biological research.

References

- Loike, J.D., Brewer, C.F., Stemlich, H., Gensler, W.J. and Horwitz, S.B.; Structure-activity study of the inhibition of microtubules assembly in vitro by podophyllotoxin and its congeners. *Cancer Res.* 1978, 38: 2688-2693.
- <http://www.hort.purdue.edu/newcrop/ncnu02/v5-527.html> (accessed 3/14/2014)
- Chan, D.A. and Giaccia, A.J.; Harnessing Synthetic Lethal Interactions in Anticancer Drug Discovery. *Nat. Rev. Drug Discov.* 2011, 10(5): 351-364.
- Markowitz, S.D. and Bertagnolli, M.M.; Molecular Origins of Cancer: Molecular Basis of Colorectal Cancer. *N. Engl. J. Med.* 2009, 361(25): 2449-2460.
- Jeedimalla, N., Johns, J. and Roche, S.; Mechanistic Investigation and Implications in the Tandem Cascade Synthesis of the Aza-podophyllotoxin Skeleton. *Tetrahedron Lett.* 2013, 54:5845-5848.